InvestorsHub Logo

oc631

11/05/13 12:33 PM

#169372 RE: genisi #169371

In this case I don't expect the shorter duration treatment to have a meaningful commercial advantage unless other DAA regimens would include Riba.





Do you think GILD will seek 8-week labeling?